



Investment Objective

The LS ARK Genomic Revolution Tracker ETP seeks to track the ARK Genomic Revolution Tracker Investment Strategy, which is designed to provide 1:1 exposure to the performance of ARK Genomic Revolution ETF, minus a fee. It invests all subscription proceeds and dividends received (net of taxes) directly into stock of ARK Genomic Revolution ETF.

Key Features

- Get 1:1 exposure to ARK Genomic Revolution ETF at low prices.
- Trade with your local broker in your own currency (no FX charges).
- Physically-backed: all moneys invested in ARK Genomic Revolution ETF.
- Liquid. Multiple market makers guarantee intraday liquidity.
- Simple to trade: like any other stock – but simpler (no need for W-8BENs).
- Simple and transparent structure: no derivatives used and full ownership of the underlying stock, so credit risk effectively negated.


Key Risks

- Highly concentrated in one stock. Less diversified ETPs are generally more volatile than more diversified ETPs.
- Investors can lose the full value of their initial investment (but not more).
- Please see the 'Risks Factors' section of the Prospectus for a more detailed discussion of the potential risks associated with an investment in this product.

PRODUCT INFORMATION

Product Name	LS ARK Genomic Revolution Tracker ETP
Underlying Security	ARK Genomic Revolution ETF
Strategy tracked	ARK Genomic Revolution Tracker Investment Strategy
Leverage Factor	No leverage
Replication	Physical (underlying stock owned)
Base Currency	USD
ISIN	XS2399368062
Structure / Legal Form	ETP / Debt Security
Countries Available	United Kingdom, Italy, Germany, France, Spain, Netherlands, Ireland, Poland and Belgium
Issuer	Leverage Shares PLC
Trustee	Apex Corporate Trustees (UK) Limited
Broker	Interactive Brokers LLC and/or Goldman Sachs & Co. LLC
Annual Management Fee	0.35%
SIPP/ISA Eligible	Yes
Sec 871(m)	Not Applicable (see FAQs)

Risk and Reward Profile



N.B. This diagram is not a UCITS synthetic risk & reward indicator and is enclosed for information purposes only

Investors should refer to the Prospectus (www.leverageshares.com) for a more complete description of the product, service providers and relevant regulatory factors.

COUNTRY	EXCHANGE	BASE CURRENCY	TRADING CURRENCY	EXCHANGE CODE	ISIN	SEDOL	BBG	RIC	WKNs	LISTING DATE
UK	London Stock Exchange	USD	USD	1ARG	XS2399368062	BNDKH39	1ARG LN	1ARG.L		14/12/2021
UK	London Stock Exchange	USD	GBx	ARKC	XS2399368062	BNDKL93	ARKC LN	ARKC.L		14/12/2021
UK	London Stock Exchange	USD	EUR	ARG1	XS2399368062	BNDKJX3	ARG1 LN	ARG1.L		14/12/2021
Netherlands	Euronext Amsterdam	USD	EUR	1ARKG	XS2399368062		1ARKG NA	1ARKG.AS		16/12/2021
Germany	Frankfurt Stock Exchange	USD	EUR	ARG1	XS2399368062		ARG1 GY	ARG1.DE	A3GWDF	01/06/2022

Contact Information

Contact us at via email at info@leverageshares.com or on Twitter at @LeverageShares. More information on Leverage Shares can we found online at www.leverageshares.com.

Disclaimer

These products are offered by Leverage Shares, and are not offered, endorsed or approved by Ark Investment Management.

Please consult an investment adviser to determine whether or not the products are suitable for you. Traders should also review the Relevant Prospectus and the Leverage Shares educational materials carefully before considering the ETPs.

No investment advice

Leverage Shares PLC is required by the FCA to clarify that it is not acting for you in any way in relation to the investment or investment activity to which this financial promotion relates. In particular, LEVERAGE SHARES PLC will not provide any investment services to you and or advise you on the merits of, or make any recommendation to you in relation to, the terms of any transaction. No representative of LEVERAGE SHARES PLC is authorised to behave in any way which would lead you to believe otherwise. LEVERAGE SHARES PLC is not, therefore, responsible for providing you with the protections afforded to its clients and you should seek your own independent legal, investment and tax or other advice as you see fit.

No offer for sale

The information contained in this financial promotion is neither an offer for sale nor a solicitation of an offer to buy securities. This financial promotion should not be used as the basis for any investment decision.

Risk Warnings

The value of an investment in ETPs may go down as well as up and past performance is not a reliable indicator of future performance. An investment in ETPs is dependent on the performance of the underlying assets of the relevant investment strategy, less costs, but it is not expected to match that performance precisely. ETPs are products which feature specific risks that prospective investors should understand before investing in them.

Securities issued by the Issuer are products involving a significant degree of risk and may not be suitable for all types of investor. Any decision to invest should be based on the information contained in the Relevant Prospectus of the Issuer (or any supplements thereto) which includes, inter alia, information on certain risks associated with an investment. The price of any securities may go up or down and an investor may not get back the amount invested. Securities are priced in US Dollars/Euros/Pounds and the value of the investment in other currencies will be affected by exchange rate movements.

Please refer to the section entitled "Risk Factors" in the relevant prospectus for further details of these and other risks associated with an investment in exchange-traded products. You should consult an independent investment adviser prior to making an investment in exchange-traded products in order to determine its suitability to your circumstances.

Prospectus

A base prospectus has been approved by the Central Bank of Ireland as competent authority under Regulation (EU) 2017/1129 with respect to the offer and listing of ETPs in Ireland and certain other EU jurisdictions listed below (the "EU Prospectus"). A base prospectus has been approved by the Financial Conduct Authority as competent authority under the United Kingdom's version of Regulation (EU) No 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC, which is part of UK law by virtue of the European Union (Withdrawal) Act 2018 with respect to the offer and listing of ETPs in the United Kingdom.

The Central Bank of Ireland has delivered to the regulators listed below certificates of approval attesting that the EU Prospectus has been drawn up in accordance with Article 25 of Regulation (EU) 2017/1129.

The EU Prospectus (and any supplements thereto) of the Issuer has been passported from Ireland into Italy (Commissione Nazionale per la Società e la Borsa), Germany (Bundesanstalt für Finanzdienstleistungsaufsicht), France (Autorité des Marchés Financiers), Spain (Comisión Nacional del Mercado de Valores), the Netherlands (the Autoriteit Financiële Markten), Poland (Komisja Nadzoru Finansowego) and Belgium (Belgian Financial Services and Markets Authority).

Investors should read the Relevant Prospectus of the Issuer before investing and should refer to the section of the Relevant Prospectus entitled 'Risk Factors' for further details of risks associated with an investment in this product.

